Court Upholds Willful Patent Infringement Verdict Against Alcon, Awards Sight Sciences $34M Plus Ongoing Royalties

summarizeSummary

A U.S. District Court upheld a jury's verdict of willful patent infringement against Alcon, awarding Sight Sciences $34 million in past damages and a 10% ongoing royalty on Hydrus® Microstent revenue through 2028.

check_boxKey Events

• Court Upholds Willful Infringement Verdict

  The U.S. District Court for the District of Delaware preserved the jury's verdict that Alcon willfully infringed three Sight Sciences patents related to the Hydrus® Microstent.

• Significant Monetary Damages Awarded

  The court awarded Sight Sciences $34 million in monetary damages for past infringement, plus supplemental damages and interest, which is a substantial amount relative to the company's market capitalization.

• Ongoing Royalty Stream Established

  An ongoing royalty of 10% of Hydrus® Microstent revenue was awarded through November 10, 2028, providing a new, long-term revenue source.

• Legal Hurdles Remain

  The final judgment is subject to appeal by Alcon, and no monetary damages will be recovered until appeals are exhausted. Additionally, ongoing *ex parte* reexamination petitions by Alcon could affect the ability to collect.

auto_awesomeAnalysis

This filing announces a critical legal victory for Sight Sciences, with a U.S. District Court upholding a jury's verdict of willful patent infringement against Alcon. The award of $34 million in past damages, representing over 16% of Sight Sciences' current market capitalization, provides a substantial potential capital infusion. Furthermore, the establishment of a 10% ongoing royalty on Alcon's Hydrus® Microstent revenue through November 2028 creates a significant future revenue stream. This development is particularly impactful given the company's recent financial baseline, which included a reduced net loss and workforce reductions, suggesting this award could materially improve its financial stability and operational runway. Investors should monitor the progress of Alcon's appeals and the ongoing *ex parte* reexamination proceedings, as these could affect the timing and ultimate collection of the awarded funds.